Autoimmune Uveitis

Autoimmune uveitis belongs to the broader category of inflammatory ocular diseases—conditions in which the body’s immune system attacks structures within the eye, causing inflammation that can damage vision. The uvea is the middle layer of the eye wall, sandwiched between the outer sclera (the white of the eye) and the inner retina (the light-sensing layer). It is composed of three interconnected structures: the iris (the colored ring that controls how much light enters the eye), the ciliary body (the structure behind the iris that produces the fluid that fills the front of the eye), and the choroid (the layer of blood vessels between the retina and the sclera). Uveitis is a collective term for inflammation of any part of the uvea, and it encompasses more than 30 distinct disease entities with different causes, presentations, and complications—ranging from mild, easily managed conditions to potentially blinding emergencies.

Autoimmune uveitis—also called noninfectious uveitis (NIU) or endogenous uveitis—refers specifically to a group of sight-threatening inflammatory eye diseases that arise not from an infection but from the immune system mistakenly attacking proteins within the eye itself. These diseases share a common mechanism: the immune system’s normal tolerance for the proteins of the eye breaks down, allowing immune cells (primarily T-cells) to enter the eye and cause inflammation. The inflammation can affect any part of the uvea or the retina, and its location largely determines the symptoms, severity, and complications a patient experiences.

Autoimmune uveitis is more common than many people realize. It affects an estimated two million Americans and accounts for approximately 10–15% of all cases of legal blindness in the United States. It is one of the leading causes of severe visual impairment in working-age adults in the developed world, with most cases affecting people between the ages of 20 and 50. Approximately 121 per 100,000 Americans are affected by noninfectious uveitis, and the U.S. incidence is 25 to 52 new cases per 100,000 persons per year. The disease can affect children as well as adults—childhood uveitis has an incidence of approximately 4 per 100,000, and the consequences of delayed diagnosis in children are particularly severe. The severity spectrum is wide: some forms cause only mild, recurrent inflammation that is easily managed with eye drops, while others cause progressive, vision-threatening damage requiring systemic immunosuppression or surgery. With early diagnosis and appropriate treatment, most patients can preserve functional vision—but delays in care significantly worsen outcomes.

Physicians classify autoimmune uveitis using the Standardization of Uveitis Nomenclature (SUN) Working Group system, which organizes cases by the anatomic location of the inflammation, the course of the disease over time (acute, recurrent, or chronic), and whether the inflammatory cells form organized granulomas (granulomatous) or not (nongranulomatous). Each of these dimensions guides diagnosis, treatment selection, and prognosis.

Anterior uveitis is the most common type, accounting for 41–60% of all cases. The inflammation is located primarily in the anterior chamber—the fluid-filled space between the cornea and the iris—with involvement of the iris and/or the ciliary body. Subtypes include iritis (inflammation of the iris alone), anterior cyclitis (inflammation of the ciliary body), and iridocyclitis (combined, the most common). Because the inflammation is at the front of the eye, it causes a painful red eye with light sensitivity. Specific disease entities in this category include:

• HLA-B27-associated acute anterior uveitis: the most common identified cause of anterior uveitis in the developed world. It is linked to seronegative spondyloarthropathies—a family of inflammatory conditions including ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and inflammatory bowel disease. Patients carry the HLA-B27 genetic marker, which is present in 6.1% of the general U.S. population but is substantially more common in this uveitis population.
• Juvenile idiopathic arthritis-associated uveitis (JIA-U): the most common cause of uveitis in children, representing 21% of all pediatric uveitis cases. Critically, it is usually entirely asymptomatic—no red eye, no pain—making it invisible without a slit-lamp examination. Up to 25% of children with oligoarticular JIA develop uveitis, and 45% already have serious complications (cataract, glaucoma) by the time they reach their first ophthalmology visit.
• Fuchs heterochromic iridocyclitis: a chronic, low-grade form, typically affecting only one eye. It is notable for causing a subtle change in the color of the affected iris (heterochromia) over time. It generally carries a relatively favorable visual prognosis compared to other chronic uveitides.

Intermediate uveitis accounts for 9–15% of all cases. The primary site of inflammation is the vitreous (the gel filling the back of the eye) and the pars plana (the ring-shaped region where the vitreous attaches to the peripheral retina). It typically presents with floaters and blurred vision but without pain or redness—a quiet eye. Pars planitis is the most common idiopathic form, with a mean onset age of 7.8 years in children. It is also associated with sarcoidosis, multiple sclerosis, and Lyme disease. Patients who carry the HLA-DR2 or HLA-DR15 genetic markers have an increased risk of developing multiple sclerosis alongside pars planitis and should be monitored accordingly.

Posterior uveitis accounts for 17–23% of cases. The inflammation involves the choroid (choroiditis), the retina (retinitis), or both (chorioretinitis), with or without inflammation of the retinal blood vessels (retinal vasculitis). Because the involved structures are at the back of the eye, there is no visible redness or pain. The only signs are visual: floaters, scotomas (blind spots), and reduced central or peripheral vision. Major disease entities include:

• Birdshot chorioretinopathy: a chronic, bilateral, granulomatous (organized nodular inflammatory) disease of the choroid and retina. It is very strongly associated with the HLA-A29 genetic marker, present in more than 90% of birdshot patients versus approximately 7% of the general population. It causes progressive visual field loss and night blindness over years to decades.
• Serpiginous choroiditis: This is a progressive, geographic pattern of destruction of the retinal pigment epithelium and choroid that spreads outward from the optic disc in an irregular, map-like pattern.
• Sympathetic ophthalmia: a bilateral granulomatous uveitis that can develop weeks to years after a penetrating injury or surgical trauma to one eye. The damaged eye’s retinal proteins enter the circulation and trigger an autoimmune attack on the uninvolved fellow eye, which can cause permanent bilateral vision loss if not treated promptly.

Panuveitis accounts for 7–32% of cases and involves all layers of the uvea simultaneously. It generally carries the highest risk of serious vision loss. The most clinically important entities are:

• Vogt–Koyanagi–Harada (VKH) disease: a bilateral granulomatous panuveitis that targets melanin-bearing cells—the pigmented cells of the choroid, the skin, the hair follicles, and the inner ear. It occurs most commonly in individuals of Hispanic, Asian, Native American, and Middle Eastern descent, and can affect children (8–16% of cases involve those younger than 16). In addition to severe bilateral uveitis with subretinal fluid, VKH causes a distinctive prodromal phase with headache, hearing changes, tinnitus, and a stiff neck, followed in its later stages by skin depigmentation (vitiligo), whitening of the eyelashes and hair (poliosis), and a characteristic orange appearance to the fundus (“sunset glow fundus”).
• Behçet disease: a systemic inflammatory vasculitis with a predilection for the historic “Silk Road” geographic corridor from East Asia to the Mediterranean. It is most common in individuals aged 10 to 30 and is strongly associated with the HLA-B51 genetic marker. The uveitis is recurrent, episodic, and severe, often with a characteristic layering of white cells at the bottom of the anterior chamber (hypopyon). Systemic features include recurrent painful oral and genital ulcers.
• Sarcoidosis-associated uveitis: The eye is one of the most commonly affected organs in sarcoidosis, with 30–60% of sarcoidosis patients having some degree of ocular involvement. Sarcoid uveitis is more prevalent in African American and Asian populations and can affect any part of the uvea. It may be the first indication that a patient has systemic sarcoidosis.

In addition to location, uveitis is classified by its time course. Acute uveitis begins suddenly and resolves within three months. Recurrent uveitis consists of repeated episodes separated by periods of at least three months of inactivity without treatment. Chronic uveitis is persistent inflammation that reactivates within three months whenever treatment is reduced. By inflammatory morphology, uveitis is classified as granulomatous (characterized by large “mutton-fat” deposits of inflammatory cells on the corneal surface and nodules on the iris, typical of sarcoidosis, VKH, and sympathetic ophthalmia) or nongranulomatous (small fine deposits, more common, typical of HLA-B27-associated and most idiopathic anterior forms). These distinctions influence which systemic diseases are suspected and which treatments are chosen.

Autoimmune uveitis develops when the eye’s natural immune privilege is overcome, allowing pathological immune responses to be directed against the eye’s own structures. Under normal circumstances, the eye is shielded from damaging immune reactions by physical barriers (the blood-retinal barrier and blood-aqueous barrier) and by active suppressive mechanisms that prevent immune cells from recognizing and attacking the retina’s own proteins. When these protective systems fail, T cells—the primary immune cells responsible for cellular immunity—enter the eye and attack native intraocular proteins. The specific proteins most commonly targeted include retinal arrestin, interphotoreceptor retinoid-binding protein (IRBP), rhodopsin, and recoverin—all proteins uniquely expressed in the retina.

Two main triggers initiate this autoimmune cascade. The first is direct ocular trauma, which exposes retinal proteins that were previously sequestered behind the blood-retinal barrier, allowing them to be recognized as foreign by the immune system. The second, and more common, is molecular mimicry—a process in which infectious organisms (bacteria or viruses) carry surface proteins structurally similar to retinal proteins. When the immune system mounts a response to the infection, it inadvertently generates immune cells that also attack the eye. Once activated, these T-cells drive two overlapping inflammatory pathways. The Th1 pathway (driven by cytokines IFN-gamma and IL-12), produces mononuclear inflammatory infiltrates. The Th17 pathway, driven by IL-17A and IL-23, drives neutrophilic inflammation and is particularly elevated in Behçet disease and VKH. The pro-inflammatory cytokine tumor necrosis factor (TNF)-alpha plays a central role across most forms of autoimmune uveitis—breaking down the blood-retinal barrier, sustaining active inflammation, and driving the tissue damage that causes visual loss. This is why TNF-alpha blockade (with adalimumab or infliximab) is the cornerstone of biologic treatment.

Genetic predisposition plays a major role in determining who develops specific forms of autoimmune uveitis and how severe their disease becomes. The strongest genetic associations are with the human leukocyte antigen (HLA) system—the genes that govern how the immune system recognizes self versus foreign proteins. HLA-B27 strongly predisposes to anterior uveitis; HLA-A29 is present in more than 90% of birdshot chorioretinopathy patients; HLA-B51 is the strongest genetic risk factor for Behçet disease; and HLA-DRB1*04 is associated with VKH disease. Mutations in the nucleotide‑binding oligomerization domain–containing protein 2 (NOD2) gene cause a rare autoinflammatory condition called Blau syndrome, characterized by the triad of uveitis, arthritis, and skin rash. Environmental and lifestyle factors also modify risk—smoking increases uveitis risk by two to three times and dramatically increases the risk of macular edema, while vitamin D deficiency is associated with approximately double the risk of uveitis development.

Several patient characteristics are associated with a higher risk of developing autoimmune uveitis or experiencing a more severe disease course.

• HLA-B27 positivity: present in approximately 6.1% of the general U.S. population, but substantially overrepresented in patients with acute anterior uveitis. Patients with HLA-B27 should be screened for the seronegative spondyloarthropathies (ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and inflammatory bowel disease) that most commonly accompany this form of uveitis.
• Underlying systemic autoimmune disease: Patients with ankylosing spondylitis develop recurrent anterior uveitis at some point in 25–40% of cases over their disease course. Thyroid disease carries a hazard ratio of 1.54 to 1.70 for uveitis. Type 1 and type 2 diabetes carry odds ratios of 1.23 to 2.01. Celiac disease carries a hazard ratio of 1.32.
• Race and ethnicity: Specific uveitides (types of uveitis) have distinct demographic profiles. Behçet disease occurs in up to 119 per 100,000 persons in Turkey versus only about 2 per 100,000 in northern Europe. VKH predominantly affects Hispanic, Asian, Native American, and Middle Eastern populations. Sarcoidosis-associated uveitis is more prevalent in African American and Asian populations.
• Age: Most autoimmune uveitis affects working-age adults (20 to 50). Behçet disease typically begins between the ages of 10 and 30. Childhood JIA-associated uveitis predominantly affects girls under 7 with antinuclear antibody (ANA)-positive oligoarticular arthritis. Late-onset uveitis in older adults raises particular concern for masquerade syndromes (lymphoma or other malignancies mimicking uveitis).

• Smoking: one of the most consistently identified modifiable risk factors. Smokers have two to three times the odds of developing uveitis compared to non-smokers, and a four-fold increased risk of macular edema in intermediate uveitis. Smoking cessation is a direct and evidence-supported therapeutic recommendation.
• Vitamin D deficiency: Associated with an odds ratio of 1.92 to 2.53 for uveitis development. Maintaining adequate vitamin D levels through diet, sunlight, or supplementation may be protective.
• Psychological stress: Elevated perceived stress scores are associated with uveitis flares. Mental health co-management, including screening for depression and anxiety, is a relevant component of comprehensive uveitis care.

• Bisphosphonates (such as zoledronic acid and alendronate, used for osteoporosis): This is associated with a relative risk of 1.45; up to 0.8% incidence with intravenous zoledronate.
• Immune checkpoint inhibitors (such as ipilimumab and nivolumab, used in cancer treatment): This is associated with a hazard ratio of 2.09 for uveitis development; incidence approximately 0.3–0.4%.
• Etanercept (a TNF receptor fusion protein used for arthritis): has an odds ratio of 5.375 for uveitis development compared to other TNF inhibitors. It is specifically not recommended for JIA-associated uveitis; adalimumab and infliximab are the preferred TNF inhibitors in this setting.

There is no universal population-level screening program for autoimmune uveitis. Screening is targeted to known at-risk populations. The most critical and most frequently missed screening imperative is the systematic ophthalmic evaluation of children with juvenile idiopathic arthritis—because JIA-associated uveitis is typically completely asymptomatic and the eye appears entirely normal (no red eye, no pain), yet serious irreversible complications are already present in 45% of children at their first ophthalmology visit.

The screening frequency for JIA-associated uveitis is determined by risk category. Children who are the highest risk—those diagnosed with JIA before age 7, who are ANA-positive, who have oligoarticular or polyarticular rheumatoid factor (RF)-negative or psoriatic JIA, and who have had JIA for four years or less—must have slit-lamp examinations every three months. Moderate-risk children are examined every six months; lower-risk JIA categories are seen annually. Screening must begin at the time of JIA diagnosis, not when symptoms appear, because the damage from asymptomatic uveitis is already occurring. For adults with a first episode of acute anterior uveitis, HLA-B27 testing is recommended—a positive result prompts screening for the underlying spondyloarthropathy. Patients with known sarcoidosis, Behçet disease, ankylosing spondylitis, and other systemic autoimmune conditions should have annual dilated ophthalmic examinations regardless of symptoms. For any patient with new-onset uveitis of unclear cause, syphilis serology (rapid plasma reagin—RPR or venereal disease research laboratory—VDRL with confirmatory testing) is recommended as universal screening regardless of clinical phenotype, and tuberculosis testing is performed based on local prevalence and before initiating immunosuppression.

Autoimmune uveitis cannot be prevented—the underlying genetic and immunological predispositions are not modifiable. Genetic counseling is available for families with Blau syndrome (NOD2 gene mutation) and other genetically linked forms. However, several steps can reduce individual risk and prevent disease flares:

• Smoking cessation: the most impactful modifiable action. Stopping smoking reduces uveitis risk (two to three times elevated in smokers) and the risk of the most visually devastating complication—macular edema in intermediate uveitis.
• Optimize vitamin D: Discuss adequate dietary intake and supplementation with your doctor, particularly if blood levels are known to be low.
• Treat underlying systemic disease: Controlling the systemic autoimmune disease that triggers uveitis (such as aggressive disease-modifying antirheumatic drug—DMARD management of ankylosing spondylitis or JIA) can reduce the frequency and severity of eye flares.
• Adhere to long-term immunomodulatory therapy: Once remission is achieved, guidelines from the American College of Rheumatology and the European League Against Rheumatism recommend maintaining steroid-sparing immunotherapy for at least two years of sustained remission before any attempt to taper, because relapse rates after early discontinuation range from 43–82% depending on the uveitis subtype.
• Genetic counseling: For families with Blau syndrome, prenatal testing and counseling about transmission risk is available.

The hallmark feature of autoimmune uveitis is that the symptoms differ dramatically depending on which part of the eye is inflamed. Anterior uveitis causes a painful red eye. Intermediate and posterior uveitis cause visual disturbances with little or no redness or pain—a “quiet eye” with significant internal disease. This disparity between external appearance and internal damage is the reason intermediate and posterior uveitis, and particularly JIA-associated anterior uveitis in children, are so often diagnosed late.

• Painful, red eye: A ring of redness (called a perilimbal ciliary flush) surrounds the cornea. This is the characteristic appearance of anterior chamber inflammation.
• Photophobia (light sensitivity): often intense and one of the most disabling acute symptoms. Any light—sunlight, fluorescent lighting, or even indoor light—can cause severe discomfort.
• Tearing: Increased tear production from ocular surface irritation.
• Blurred vision: This is typically mild to moderate in acute anterior uveitis; worse if the lens or posterior segment becomes involved over time.
• Small or irregular pupil: Inflammation causes the iris to stick to the front surface of the lens (posterior synechiae), distorting the pupil shape and preventing it from dilating normally.
• Hypopyon: a visible layering of white cells that settles at the bottom of the anterior chamber, visible as a white crescent at the base of the cornea. This is a dramatic sign of severe anterior uveitis, particularly characteristic of Behçet disease.

• Floaters: moving spots, strands, or clouds in the visual field caused by inflammatory cells and debris in the vitreous gel. This is often the first and most prominent symptom.
• Blurred vision: gradually worsening visual clarity. Most patients have no pain and no red eye—the distinction from anterior uveitis is clinically critical.

• Floaters: as in intermediate uveitis
• Significantly decreased vision: can be severe and sudden, depending on whether the macula (the center of the retina responsible for sharp central vision) is involved
• Scotomas (blind spots): fixed dark areas in the visual field corresponding to areas of retinal damage
• Photopsia (flashing lights): from retinal irritation or traction
• Metamorphopsia (distorted vision): straight lines appear wavy, caused by macular edema or epiretinal membrane pulling on the foveal photoreceptors
• No redness or pain: the eye appears externally normal; this is the most clinically dangerous feature: patients may not realize they are losing vision until damage is advanced

The following conditions develop as consequences of sustained or recurrent inflammation, or as side effects of prolonged corticosteroid use. They are the primary causes of permanent vision loss in autoimmune uveitis and are why monitoring is lifelong:

• Cataract (clouding of the lens): present in 23–83% of JIA-associated uveitis patients. Both the inflammation itself and the corticosteroid drops used to treat it contribute to cataract formation.
• Glaucoma (optic nerve damage from elevated eye pressure): present in 17–28% of JIA-associated uveitis patients. Inflammation blocks the eye’s natural drainage channels, raising intraocular pressure.
• Cystoid macular edema (CME): fluid accumulation in the central retina from leaky retinal blood vessels. This is the leading cause of vision loss in uveitis, affecting 2–30% of JIA-associated uveitis patients.
• Band keratopathy: This is a horizontal band of calcium deposits across the front surface of the cornea, visible as an opaque white stripe, affecting 14–46% of JIA-associated uveitis patients.
• Posterior synechiae (iris adhesions to the lens): present in 18–44% of JIA-associated uveitis patients. It distorts the pupil and can cause acute angle-closure glaucoma if the adhesions completely block fluid circulation.
• Epiretinal membrane: This is a thin fibrous layer on the retinal surface, causing central vision distortion.
• Retinal detachment: This is a sight-threatening emergency requiring urgent surgery.
• Amblyopia (lazy eye): a uniquely pediatric complication. In children whose visual pathways are still developing, temporary vision deprivation from uveitis, cataract, or glaucoma can cause a permanent reduction in visual acuity if not treated during the critical developmental window.

• In children (JIA-associated uveitis): The disease is classically silent. There is no red eye, no pain, no photophobia. Parents may notice the child sitting too close to the television, squinting, or developing a visible eye turn. Pediatricians may notice an asymmetric red reflex in photographs. The diagnosis is made only by slit-lamp examination during scheduled JIA surveillance, underscoring why the screening schedule is not negotiable.
• In adolescents and young adults with tubulointerstitial nephritis and uveitis (TINU) syndrome: a flu-like prodrome followed by flank or back pain from kidney inflammation precedes bilateral anterior uveitis. The median age is 15 years, and 75% of patients are female. Urine testing for a kidney protein called beta-2-microglobulin supports the diagnosis.
• In adults with Behçet disease: Recurrent episodic attacks of severe anterior uveitis—sometimes with visible hypopyon—alternate with periods of quiet. Concurrent or preceding oral ulcers (canker sores) and genital ulcers are the key systemic clues. Posterior segment involvement with retinal vasculitis is the most vision-threatening manifestation.
• In adults with VKH disease: The prodromal phase brings headache, orbital pain, stiff neck, sensorineural hearing loss, and tinnitus—symptoms resembling meningitis. The acute uveitic phase then produces bilateral blurry vision with subretinal fluid accumulation. The later chronic phase is marked by skin depigmentation, whitening of the hair and eyelashes, and the sunset glow fundus appearance.

Autoimmune uveitis is diagnosed and managed by an ophthalmologist, often in coordination with a rheumatologist or internist when a systemic cause is suspected. Because many forms of uveitis mimic infectious eye disease—and because the treatments for autoimmune versus infectious uveitis are diametrically opposite (immunosuppression makes infectious uveitis worse)—excluding infection is the first priority in any new uveitis evaluation. Approximately 27–51% of uveitis cases in the United States and Europe have no identifiable systemic cause even after thorough workup. A tailored diagnostic approach guided by the uveitis phenotype is preferred over a standard battery for every patient.

• Slit-lamp biomicroscopy: the gold standard for diagnosing and grading uveitis. The ophthalmologist uses a specialized microscope with a bright light beam to examine the anterior chamber (counting inflammatory cells and measuring protein leakage using the SUN grading criteria), identify keratic precipitates on the corneal surface, detect iris nodules and posterior synechiae, and determine whether the inflammation is granulomatous or nongranulomatous. This examination is also extended to the dilated posterior segment to assess the vitreous, retina, and optic nerve.
• Goldmann applanation tonometry: This measures intraocular pressure, which can be elevated from inflammatory damage to the eye’s drainage angle or from corticosteroid use, or abnormally low from ciliary body shutdown in severe disease.
• Indirect ophthalmoscopy: This evaluates the peripheral retina, vitreous haze, and posterior choroid for signs of posterior or panuveitis, including retinal vasculitis, choroidal lesions, and optic nerve swelling.
• Visual acuity and visual field testing: establishes baseline function. Humphrey automated visual field testing detects glaucomatous field loss.

• Optical coherence tomography (OCT): the essential imaging tool for macular assessment. OCT detects and precisely quantifies cystoid macular edema—the leading cause of vision loss in uveitis—and monitors the response to treatment. It also measures retinal nerve fiber layer thickness for glaucoma monitoring. Anterior segment OCT enables standardized quantitative measurement of anterior chamber cells and flare.
• Fluorescein angiography (FA): an intravenous dye-based imaging study that maps retinal vascular leakage, reveals active retinal vasculitis, identifies optic disc hyperfluorescence, and detects retinal neovascularization in conditions such as Behçet disease. Essential for posterior segment assessment and surgical planning.
• Indocyanine green angiography (ICGA): evaluates choroidal circulation. Particularly useful in VKH disease and birdshot chorioretinopathy, where the choroid is the primary site of granulomatous inflammation.
• B-scan ultrasonography: provides cross-sectional imaging of the posterior eye when the view is blocked by dense cataract or vitreous hemorrhage. Detects retinal detachment and choroidal lesions.
• Wide-field fundus photography and fundus autofluorescence (FAF): photograph and document retinal lesions and monitor disease progression. FAF reveals patterns of RPE damage not visible on standard photography.

All patients with new-onset uveitis, regardless of clinical type, should have syphilis serology (RPR or VDRL with confirmatory treponemal testing) because ocular syphilis can mimic virtually any form of uveitis. Tuberculosis testing (QuantiFERON®-TB Gold or tuberculin skin test) is performed based on local prevalence and is mandatory before starting biologic immunosuppression. Additional testing is tailored by the uveitis phenotype. For adult anterior uveitis: HLA-B27 typing, complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and chest X-ray. For children: ANA and HLA-B27. For intermediate, posterior, or panuveitis: serum angiotensin-converting enzyme (ACE) and lysozyme for sarcoidosis; chest computed tomography (CT); ANA and anti-dsDNA for lupus; Lyme serology in endemic regions. Behçet disease and VKH are primarily clinical diagnoses based on established international criteria—no single blood test confirms either. In selected complex or atypical cases, aqueous or vitreous fluid is sampled for polymerase chain reaction—PCR (to detect herpesviruses, toxoplasma, and tuberculosis), cytology (to exclude intraocular lymphoma, which can mimic uveitis in adults over 50), and cytokine analysis. A ratio of IL-10 to IL-6 above a threshold in vitreous fluid is suggestive of intraocular lymphoma rather than inflammatory uveitis.

Autoimmune uveitis is not curable for most patients, but it is highly manageable with the right treatment plan. The goals of treatment are to suppress active inflammation promptly, prevent recurrence, preserve visual function, and minimize the side effects of long-term therapy. Treatment follows a stepwise escalating ladder: topical (eye drop) therapy first, then local corticosteroid injections or implants, then systemic corticosteroids for severe or bilateral disease, then steroid-sparing immunosuppressive agents (conventional DMARDs), and finally biologic agents for refractory cases. Multidisciplinary care—with the ophthalmologist, rheumatologist, and primary care physician working in coordination—is the standard of care for any patient requiring systemic immunosuppression. Your care team will determine the right combination of treatments for your specific form of uveitis, its severity, and your overall health.

Corticosteroids (steroid medications) are the most rapidly effective anti-inflammatory agents available and are the backbone of acute uveitis management. They can be delivered locally—directly to the eye—or systemically, depending on the location and severity of disease.

For anterior uveitis, prednisolone acetate 1% eye drops are the first-line standard of care, applied frequently during the acute phase and tapered as the inflammation resolves. Difluprednate 0.05% ophthalmic emulsion is a more potent topical corticosteroid reserved for severe anterior inflammation or cystoid macular edema. Both carry a risk of elevated intraocular pressure and cataract formation with prolonged use, and long-term topical corticosteroids as a sole treatment strategy are not recommended—steroid-sparing agents are needed for recurrent or chronic disease. For intermediate, posterior, or panuveitis that requires more sustained local therapy, three U.S. Food and Drug Administration (FDA)-approved intravitreal (inside the eye) corticosteroid implants are available. The dexamethasone intravitreal implant (Ozurdex®, 0.7 mg) is a biodegradable implant injected in clinic that releases dexamethasone over three to six months; it is FDA-approved for noninfectious intermediate and posterior uveitis. The fluocinolone acetonide implant 0.18 mg (Yutiq®) is a non-biodegradable injectable implant that provides sustained corticosteroid release for up to three years, FDA-approved for chronic noninfectious uveitis affecting the posterior segment. The fluocinolone acetonide implant 0.59 mg (Retisert®) provides sustained release for approximately 2.5 years and is surgically implanted in the operating room, sutured to the eye wall; it is FDA-approved for noninfectious intermediate, posterior, and panuveitis, but is associated with cataract formation in approximately 95% of patients and elevated intraocular pressure requiring treatment in approximately 60%. Periocular (around-the-eye) injection of triamcinolone acetonide into the sub-Tenon space is an injectable alternative to intravitreal implants for intermediate and posterior disease. For severe bilateral or systemic disease, oral prednisone and intravenous methylprednisolone (pulse dosing for acute emergencies such as the uveitic phase of VKH) provide systemic control. However, long-term oral corticosteroids as sole treatment are not recommended due to their cumulative side effects—osteoporosis, diabetes, hypertension, and opportunistic infections—and steroid-sparing treatment should be initiated within two weeks of starting any systemic corticosteroid course.

For recurrent or chronic uveitis requiring long-term immunosuppression, disease-modifying antirheumatic drugs (DMARDs) are introduced to control inflammation without the side effects of sustained corticosteroid use. The three most commonly used first-line steroid-sparing agents are methotrexate, mycophenolate mofetil, and azathioprine.

Methotrexate (7.5 to 25 mg weekly, taken orally or by subcutaneous injection) is considered the first-choice steroid-sparing agent for most uveitis categories. It achieves approximately 73% response rates in children with JIA-associated uveitis. In adults with posterior uveitis, it achieves remission in approximately 52% of patients. It is the most effective conventional DMARD for sarcoidosis-associated uveitis. Methotrexate requires monthly monitoring of liver function tests (elevated in approximately 13% of patients), and it is teratogenic—it must be discontinued at least three months before a planned pregnancy. Folic acid supplementation is taken alongside methotrexate to reduce side effects. Mycophenolate mofetil (1 to 3 grams per day) is a comparable alternative, with the First-line Antimetabolites as Steroid-Sparing Treatment (FAST) uveitis trial demonstrating non-inferior overall efficacy to methotrexate for noninfectious intermediate and posterior uveitis. It is also teratogenic. Azathioprine (1 to 2.5 mg/kg/day) is another first-line option that has a relatively safe profile for use during pregnancy. For refractory cases, cyclosporine A—which directly blocks T-cell activation by inhibiting IL-2 signaling—provides effective T-cell–targeted immunosuppression, particularly in anterior and posterior uveitis. Cyclophosphamide is reserved for the most severe, vision-threatening cases such as refractory Behçet disease vasculitis, given its significant toxicity profile.

Adalimumab (brand name Humira®, also available as biosimilars) is the only FDA-approved biologic agent for autoimmune uveitis. It works by blocking TNF-alpha—a key cytokine that drives inflammation throughout the body and specifically disrupts the blood-retinal barrier in uveitis. It is administered as a subcutaneous injection at home every two weeks. FDA approval was granted in 2016 for adults with noninfectious intermediate, posterior, and panuveitis, and in 2018 for pediatric patients. In the pivotal VISUAL I clinical trial (active uveitis at enrollment), adalimumab extended the median time to treatment failure from 13 weeks with placebo to 24 weeks, and reduced the treatment failure rate from 78.5% to 54.5%. In the VISUAL II trial (inactive disease at enrollment), adalimumab significantly reduced the risk of uveitis recurrence. The pediatric Adalimumab for Decreasing JUvenile VIritis Trial in Europe (ADJUVITE trial) showed that children on adalimumab were more than twice as likely to have inflammation improvement at two months compared to placebo. All patients must be screened for tuberculosis before starting adalimumab, and live vaccines are contraindicated during treatment. Rare but serious risks include serious infections, reactivation of tuberculosis or hepatitis B, and demyelinating disorders.

When adalimumab is insufficient or not tolerated, several other biologics are used off-label. Infliximab (Remicade®, given by intravenous infusion) is widely used in Behçet disease-associated uveitis and JIA-associated uveitis refractory to adalimumab, sometimes at doses up to 20 mg/kg every four weeks. Tocilizumab (Actemra®, anti-IL-6 receptor) is a promising second-line biologic in JIA-associated uveitis; the Phase 2 Anti‑PD‑1 Therapy In Treatment of Uveitis: Dose‑finding Evaluation (APTITUDE) trial showed 33% of patients with refractory JIA-U met the primary response endpoint at 12 weeks. Abatacept (Orencia®)—which blocks the T-cell costimulation signal required for T-cell activation—achieves response in 52–57% of refractory JIA-U patients. Rituximab (Rituxan®) targets B cells and is used for refractory posterior uveitis and panuveitis; durable remission has been reported in long-standing refractory JIA-U at more than 44 months of mean follow-up. Anakinra (Kineret®, an IL-1 receptor antagonist) is effective in Behçet disease. Secukinumab (anti-IL-17A) is used in some cases of sarcoidosis-associated uveitis. Janus kinase (JAK) inhibitors—including tofacitinib (currently the only JAK inhibitor approved for use in children for polyarticular JIA)—are emerging as oral alternatives to biologics, with baricitinib currently in a Phase 3 randomized controlled trial in childhood uveitis.

Surgery is used to treat uveitis complications that cannot be managed medically and to place long-acting corticosteroid implants. All elective uveitis surgery should be deferred until inflammation has been controlled for a minimum of three months, as operating in an inflamed eye dramatically increases the risk of complications. Pars plana vitrectomy (PPV)—removal of the vitreous gel through small incisions in the sclera—is used to clear persistent vitreous opacification, remove epiretinal membranes, repair retinal detachment, and, in some cases, to take a diagnostic vitreous sample. Cataract surgery (phacoemulsification with intraocular lens implantation) is performed for visually significant uveitic cataract, which affects 23–83% of JIA-U patients. Perioperative corticosteroids (topical, periocular, and sometimes oral) are essential to prevent postoperative inflammation and macular edema. For uveitic glaucoma that cannot be controlled with eye drops, trabeculectomy (surgical creation of a new drainage channel) or glaucoma drainage implants (Ahmed® or Baerveldt® tube shunts—named for their inventors, these devices provide an alternate route for aqueous humor to exit the eye) are used. Glaucoma drainage implants are generally preferred over trabeculectomy in uveitic glaucoma because of lower long-term failure rates in the inflammatory environment. Panretinal photocoagulation (laser applied to the peripheral retina) is used for peripheral retinal neovascularization in pars planitis and Behçet disease.

Cystoid macular edema—the leading cause of vision loss in uveitis—is treated with topical nonsteroidal anti-inflammatory drugs—NSAIDs (ketorolac eye drops), periocular or intravitreal corticosteroids, and off-label anti-vascular endothelial growth factor (VEGF) agents. The PeriOcular vs. INTravitreal corticosteroids (POINT) trial demonstrated that intravitreal triamcinolone is superior to periocular triamcinolone for acute CME. Band keratopathy is treated with ethylenediaminetetraacetic acid (EDTA) chelation (a chemical solution applied to the corneal surface to dissolve the calcium deposits) or laser photorefractive keratotomy. Posterior synechiae are treated with dilating drops (atropine or cyclopentolate) to break the iris-lens adhesions, or surgically if pupillary block glaucoma develops. Intraocular pressure elevation from corticosteroids or inflammatory glaucoma is managed with topical pressure-lowering medications (beta-blockers, carbonic anhydrase inhibitors, or prostaglandin analogues), escalating to glaucoma surgery if drops are insufficient. Amblyopia in children is treated with patching of the stronger eye while the weaker eye’s vision is rebuilt—but aggressive treatment of the underlying uveitis to restore visual clarity is the essential prerequisite.

Autoimmune uveitis is a chronic, lifelong condition for most patients, requiring ongoing ophthalmic monitoring and often long-term medical management. The frequency of follow-up visits varies from every three months in high-risk patients (such as children with JIA) to annually in stable, well-controlled disease. Many patients on biologic therapy or systemic immunosuppressants need regular blood tests to monitor for side effects and must avoid live vaccines and take precautions against infection. The practical implications of this level of monitoring are real—uveitis is demanding to manage, and it affects employment, driving, and daily activities when vision is compromised.

But the trajectory is not uniformly grim. Many patients with properly managed autoimmune uveitis maintain functional vision throughout their lives and live full, productive lives—particularly those diagnosed early, treated promptly, and adherent to their monitoring schedule. The outcomes for patients treated early and aggressively are substantially better than those treated late. Depression and anxiety are significantly elevated in the uveitis population and are real, valid complications of this disease—discussing mental health with your care team and connecting with patient support communities such as the Ocular Immunology and Uveitis Foundation (uveitis.org) can make a meaningful difference. The most important self-monitoring step you can take is to know the warning signs that require a same-day call to your ophthalmologist: any new or dramatically increased floaters, sudden vision change, painful red eye, or new photophobia. Acting on these symptoms promptly—rather than waiting and watching—is the single most important patient behavior for preventing permanent visual damage.

To further your understanding of your diagnosis and to contribute to cutting-edge research, consider participating in a clinical trial so clinicians and scientists can learn more about causes, symptoms, treatment, and prevention of autoimmune uveitis and related disorders. Clinical research uses human volunteers to help researchers learn more about a disorder and perhaps find better ways to safely detect, treat or prevent disease.

Se necesitan voluntarios de todo tipo: personas sanas o que padezcan alguna enfermedad, de todas las edades, sexos, razas y etnias, para garantizar que los resultados del estudio se apliquen al mayor número de personas posible y que los tratamientos sean seguros y eficaces para todos los que los utilicen.